29.00p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Faron Pharmaceuticals Oy
Its shares trade on LSE under the ticker FARN.L. It has been listed since 17 November 2015. In the fiscal year to 31 December 2018, it reported revenue of €19,000 and a net loss of €20.1m. At that date it held total assets of €8.0m and shareholders' equity of €369,000.
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company. The company is headquartered in Turku, Lansi-Suomen. The company went IPO on 2015-11-17. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The firm has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. The company is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. The company may be used alone or in combination with other immune checkpoint molecules.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Nov 2015
- Employees
- 24
- Website
- faron.com ↗
Leadership
Pay as last reported
- Mr. Tuomo PaetsiNon-Executive Chairman of the Board
- Dr. Juho JalkanenChief Executive Officer, Executive Director€17,164
- Mr. Yrjo WichmannChief Financial Officer€193,156
- Dr. Maija HollmenChief Scientific Officer
- Dr. Markku JalkanenExecutive Director€449,986
- Dr. Petri BonoChief Medical Officer
- Mr. Ralph HughesChief Business Officer
- Mr. Colin BondNon-Executive Director
- Dr. Marie-Louise FjallskogNon-Executive Director
- Ms. Christine RothNon-Executive Director
- Mr. John PoulosNon-Executive Independent Director€40,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Faron Pharmaceuticals Oy has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company boasts a strong portfolio of innovative and high-quality pharmaceutical products. These products have been developed through extensive research and development, ensuring their effectiveness and reliability.
- Additionally, Faron Pharmaceuticals Oy has a highly skilled and knowledgeable workforce. The employees possess expertise in various areas, such as research, clinical trials, manufacturing, and marketing. This expertise enables the company to maintain a competitive edge and ensure the delivery of high-quality products to customers.
- Furthermore, the company has established strong partnerships and collaborations with key stakeholders in the healthcare industry. These partnerships allow Faron Pharmaceuticals Oy to access additional resources, expertise, and distribution channels, leading to increased market reach and profitability.
Weaknesses
- Despite its strengths, Faron Pharmaceuticals Oy also faces certain weaknesses that could hinder its growth and success. One weakness is the company's limited presence in international markets. While it has achieved significant success in its domestic market, expanding into new geographical regions and navigating diverse regulatory environments may pose challenges.
- Additionally, Faron Pharmaceuticals Oy relies heavily on its key products for revenue generation. This concentration increases the company's vulnerability to changing market dynamics, potential patent expirations, and increased competition. Diversification of its product portfolio is crucial to mitigate these risks and ensure long-term sustainability.
Opportunities
- There are several opportunities for Faron Pharmaceuticals Oy to capitalize on in the pharmaceutical industry. One significant opportunity lies in the increasing global demand for innovative healthcare solutions. By investing in research and development, the company can develop new products that target unmet medical needs, thereby expanding its customer base and generating additional revenues.
- Furthermore, the growing prevalence of chronic diseases and an aging population present an opportunity for Faron Pharmaceuticals Oy to develop specialized medications and treatments. By strategically focusing on these areas, the company can establish itself as a leader in disease management and improve patient outcomes.
Threats
- Faron Pharmaceuticals Oy faces certain threats that may hinder its growth and profitability. One significant threat is intense competition within the pharmaceutical industry. The presence of established pharmaceutical giants, as well as emerging companies, poses challenges in terms of market share and pricing pressure.
- Additionally, regulatory changes and stringent approval processes can delay the launch of new products and increase compliance costs. Adapting to these changes while remaining competitive can be a challenge for Faron Pharmaceuticals Oy.
- Finally, global economic uncertainties and potential disruptions in the supply chain pose threats to the company's operations. Risks such as trade wars, natural disasters, and pandemics can impact production, distribution, and overall business continuity.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.